Bayer's Debt Sprint Hits a Speed Bump: Short Sellers Circle as Legal Clock Resets

Bayer's debt falls faster than expected, but short interest surges 94.9% as analysts question if the 86% rally is sustainable.

The gap between Bayer's operational turnaround and its market valuation has rarely looked wider. The Leverkusen-based conglomerate is burning through its debt mountain faster than management ever promised, yet the shares are now trading roughly 11 percent below their 52-week high of 53.86 euros — and a growing chorus of short sellers is betting the rally has run its course.

At the heart of the tension lies a simple arithmetic problem. Bayer now expects net financial debt of just 29 to 30 billion euros by year-end, a sharp improvement over the 32 to 33 billion euros previously guided. Two forces are driving the acceleration: a robust performance from the Crop Science division and a reported agreement to sell a stake in the contraception business to Apollo. The equity market has taken notice — the stock has climbed 86 percent from its November 2025 low of 25.78 euros and sits 29 percent higher on a twelve-month basis. But the question investors are wrestling with is whether this is a structural re-rating or a one-off event dressed up as a turnaround.

The Short Squeeze That Isn't

The bears are making their presence felt. Short interest jumped 94.9 percent month-on-month to 522,716 shares as of July 31, according to media reports — a striking surge that suggests a growing cohort of market participants expects near-term downside. That bearish positioning aligns with the cautious stance from the sell side. Jefferies analyst Michael Leuchten reiterated a "Hold" rating on August 10 with a price target of 46.00 euros, arguing that a breakup of the agri-pharma giant remains unlikely in the near term — a structural question that has hovered over the stock for years without resolution.

The stock's recent price action reflects this ambivalence. After closing Thursday at 48.44 euros, the shares slipped 1.6 percent on Friday to 47.67 euros. The pullback leaves the equity 17 percent above its 200-day moving average of 40.79 euros, a technical cushion that has held through the recent consolidation.

Crop Science Carries the Load

The bull case rests squarely on the agricultural division. Crop Science delivered second-quarter revenue of 4.910 billion euros, up 3.5 percent, while EBITDA before special items surged 30.2 percent to 902 million euros. That operational strength has allowed management to lift full-year guidance: Bayer now projects 2026 revenue of 44.7 to 46.7 billion euros and adjusted earnings per share of 4.20 to 4.70 euros, up from the previous range of 4.10 to 4.60 euros.

The second-quarter adjusted EPS of 0.95 euros blew past the analyst consensus of 0.73 euros. But the pharma division tells a more sobering story. Revenue came in at 4.458 billion euros, while EBITDA before special items fell 3.6 percent to 1.055 billion euros. Core EPS of 0.95 euros was down 16.7 percent from the year-ago figure of 1.14 euros, a decline Bayer attributes to normalized tax charges and weaker reconciliation segment earnings. The patent expiries on Xarelto and Eylea continue to drain revenue, even as Nubeqa for prostate cancer and Kerendia for kidney disease partially offset the losses.

A Small Win in Canada, a Big Question in Missouri

On the regulatory front, Bayer secured a modest but strategically meaningful approval last Monday: Health Canada expanded the label for LYNKUET (fezolinetant) to cover vasomotor symptoms triggered by adjuvant endocrine therapy in breast cancer patients. The move extends the drug's reach beyond its original indication and signals that Bayer is deliberately broadening its pharma portfolio beyond core US and European markets. The near-term revenue impact is likely limited, but the indication addresses a stable, recurring-demand segment — hot flashes are among the most common side effects of endocrine cancer therapies.

The more consequential legal event, however, remains in flux. The hearing originally scheduled for August 19 to finalize the glyphosate class-action settlement was postponed, prolonging the legal uncertainty that has weighed on the stock for years. A Missouri court is now set to consider final approval of the Roundup settlement on September 14. The outcome will likely determine whether the risk premium Bayer has shed over the past twelve months proves durable — or whether fresh legal overhang sends the shares back toward the 50-day moving average at 46.78 euros and below.

The Balancing Act

With the RSI at a neutral 50.1, the chart offers no immediate signals of overheating. The technical setup suggests room for further upside as long as Crop Science continues to offset pharma weakness and the debt reduction stays on track. But the margin for error is thin. A stumble in agricultural momentum, another legal delay, or a further build in short positions could quickly test the stock's resolve.

The next major checkpoint comes November 3, when Bayer reports third-quarter numbers. Until then, the debate over a potential conglomerate split, the trajectory of short interest, and the September 14 court date will keep the shares in a tug-of-war between operational progress and structural skepticism.